The Simple HM3 MagLev technology is far superior to the H/MVAD overly complex blood-flow technology and allows much further efficacy and cost reduction.
The FILVAS fully implantable technology is having great success in testing and should eliminate Heart Transplants. The Bionic Man has arrived.
THOR will fully dominate the HUGE multi-BILLION$$$ Heart Failure market in both implants and in the Acute Catheter Lab.
Meanwhile THOR's Free-Cash-Flow is outstanding and will continue to sharply reduce share count with continuous buy-backs. And they have ZERO DEBT!!!!
I have not listened to the conf call yet. Did the CEO actually reference testing of the HeartMate III on the call?